NCT00639262View on ClinicalTrials.gov

Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Brain MetastasesPrimary Brain Tumors
Interventions
DRUG

Sorafenib

Sorafenib 200mg twice daily during XRT and 30 days after. (Sorafenib will be escalated for both cohorts to determine maximum tolerated dose)

DRUG

Temozolomide

For Cohort 2 - Gliomas only.

RADIATION

Radiotherapy

Radiation Therapy (XRT)

Trial Locations (1)

19107

Thomas Jefferson University, Philadelphia

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT00639262 - Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors | Biotech Hunter | Biotech Hunter